Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
复制标题
DOI：
10.1056/nejmoa1812389
复制
发表时间：
2019-01-24
影响因子：
158.5
通讯作者：
Sabatine, M. S.
中科院分区：
文献类型：
--
作者：
Wiviott, S. D.;Raz, I.;Sabatine, M. S.
Dapagliflozin是一种钠-葡萄糖协同转运蛋白2的选择性抑制剂，可促进2型糖尿病患者的糖尿，其心血管安全性尚不明确。主要安全性结局是主要心血管不良事件（MACE）的复合终点，定义为心血管死亡、心肌梗死或缺血性卒中。主要疗效结局为MACE和心血管死亡或因心力衰竭住院的复合终点。次要疗效结局为肾脏复合终点（估计肾小球滤过率降低>= 40%，
BACKGROUNDThe cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.METHODSWe randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke. The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure. Secondary efficacy outcomes were a renal composite (>= 40% decrease in estimated glomerular filtration rate to